keyword
MENU ▼
Read by QxMD icon Read
search

melanoma Stage 3

keyword
https://www.readbyqxmd.com/read/29453871/examining-the-incidence-and-presentation-of-melanoma-in-the-cardiothoracic-transplant-population
#1
Charles J Puza, Adela R Cardones, Paul J Mosca
Importance: The immunosuppression vital to maintaining transplanted organs comes with an increased incidence of cutaneous neoplasms. Understanding the genesis of malignant melanoma (MM) in transplant subpopulations is necessary for adequate disease surveillance. Objective: To determine the incidence and timing of presentation of MM in the cardiothoracic (heart and/or lung) transplant (CTT) population. Design, Setting, and Participants: This was a retrospective cohort study of 1164 patients who underwent a CTT from 2001 through 2016 with a median follow-up time of 4...
February 16, 2018: JAMA Dermatology
https://www.readbyqxmd.com/read/29450912/association-of-clinicopathological-features-of-melanoma-with-total-naevus-count-and-a-history-of-dysplastic-naevi-a-cross-sectional-retrospective-study-within-an-academic-centre
#2
S Y Tan, L C Strazzulla, X Li, J J Park, S J Lee, C C Kim
BACKGROUND: High naevus count (HNC) (≥ 50 naevi) and presence of dysplastic naevi (DN) are risk factors for malignant melanoma (MM); however, MMs also occur in patients with low naevus count (LNC) (< 50 naevi) and in patients without DN. Little is known about differences between MMs in these groups. AIM: To characterize the clinicopathological differences between MMs in patients with HNC and those in patients with LNC, with or without biopsy-proven DN. METHODS: This was a cross-sectional retrospective chart review of 281 patients with MM seen between April 2013 and March 2014 at an academic pigmented lesion clinic (Boston, MA, USA)...
February 16, 2018: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29433571/granulomatous-sarcoid-like-lesions-associated-with-checkpoint-inhibitors-a-marker-of-therapy-response-in-a-subset-of-melanoma-patients
#3
Michael T Tetzlaff, Kelly C Nelson, Adi Diab, Gregg A Staerkel, Priyadharsini Nagarajan, Carlos A Torres-Cabala, Beth A Chasen, Jennifer A Wargo, Victor G Prieto, Rodabe N Amaria, Jonathan L Curry
BACKGROUND: Immune checkpoint therapy has dramatically changed the landscape of cancer therapy, providing an efficacious and durable therapeutic option for patients with advanced-stage disease. However, dermatologic toxicities are a well-recognized side effect in patients receiving this therapy. A spectrum of immune related adverse events (irAEs) involving the skin can occur and include immunobullous disorders, lichenoid dermatitis, and vitiligo. Granulomatous/sarcoid-like lesions are now being recognized with the current class of checkpoint inhibitors (CPIs) that involve the dermis, the subcutaneous tissue (panniculitis), and lymph nodes...
February 12, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29414294/multiple-sclerosis-onset-after-granulocyte-macrophage-colony-stimulating-factor-withdrawal
#4
J Chong, M Cohen, E Waubant
A 51-year old woman with stage III melanoma participated in a phase II clinical trial in which she received subcutaneous rhGM-CSF injections for 3 years. She was in remission by the end of the trial. Seven months after discontinuing GM-CSF she had her first MS event. The unique timeline of rh-GM-CSF injections in a melanoma trial, during which yearly MRI scans showed subtle stable demyelination followed by RRMS onset shortly after discontinuation of treatment, may provide some insight on the role of GM-CSF in MS...
February 1, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29409139/withdrawn-chemoimmunotherapy-versus-chemotherapy-for-metastatic-malignant-melanoma
#5
REVIEW
Andre D Sasse, Emma C Sasse, Luciana Go Clark, Otavio Augusto Camara Clark
BACKGROUND: Malignant melanoma, one of the most aggressive of all skin cancers, is increasing in incidence throughout the world. Surgery remains the cornerstone of curative treatment in earlier stages. Metastatic disease is incurable in most affected people, because melanoma does not respond to most systemic treatments. A number of novel approaches are under evaluation and have shown promising results, but they are usually associated with increased toxicity and cost. The combination of chemotherapy and immunotherapy has been reported to improve treatment results, but it is still unclear whether evidence exists to support this choice, compared with chemotherapy alone...
February 6, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29402264/performance-of-a-prognostic-31-gene-expression-profile-in-an-independent-cohort-of-523-cutaneous-melanoma-patients
#6
Jonathan S Zager, Brian R Gastman, Sancy Leachman, Rene C Gonzalez, Martin D Fleming, Laura K Ferris, Jonhan Ho, Alexander R Miller, Robert W Cook, Kyle R Covington, Kristen Meldi-Plasseraud, Brooke Middlebrook, Lewis H Kaminester, Anthony Greisinger, Sarah I Estrada, David M Pariser, Lee D Cranmer, Jane L Messina, John T Vetto, Jeffrey D Wayne, Keith A Delman, David H Lawson, Pedram Gerami
BACKGROUND: The heterogeneous behavior of patients with melanoma makes prognostication challenging. To address this, a gene expression profile (GEP) test to predict metastatic risk was previously developed. This study evaluates the GEP's prognostic accuracy in an independent cohort of cutaneous melanoma patients. METHODS: This multi-center study analyzed primary melanoma tumors from 523 patients, using the GEP to classify patients as Class 1 (low risk) and Class 2 (high risk)...
February 5, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29399415/melanoma-induced-immunosuppression-is-mediated-by-hematopoietic-dysregulation
#7
Neha Kamran, Youping Li, Maria Sierra, Mahmoud S Alghamri, Padma Kadiyala, Henry D Appelman, Marta Edwards, Pedro R Lowenstein, Maria G Castro
Tumors are associated with expansion of immunosuppressive cells such as tumor associated macrophages (TAMs), regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs). These cells promote tumor growth, angiogenesis, metastasis and immune escape. Cancer patients frequently present symptoms such as anemia, leukocytosis and/or cytopenia; associated with poor prognosis. To uncover tumor-mediated hematopoietic abnormalities and identify novel targets that can be harnessed to improve tumor-specific immune responses, we investigated the hematopoietic stem and progenitor cell compartment in melanoma bearing mice...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29399266/a-retrospective-analysis-of-surveillance-adherence-of-patients-after-treatment-of-primary-cutaneous-melanoma
#8
Jeave Reserva, Monica Janeczek, Cara Joyce, Amanda Goslawski, Hwala Hong, Feng-Ning Yuan, Neelam Balasubramanian, Laura Winterfield, James Swan, Rebecca Tung
BACKGROUND: Melanoma surveillance serves to identify new primary melanomas and curable locoregional or early distant recurrences. Although an optimal melanoma surveillance strategy has not been determined, several clinical guidelines exist. OBJECTIVE: The aim of this study was to identify demographic and clinico-pathologic variables associated with poor adherence to National Comprehensive Cancer Network (NCCN) melanoma surveillance guidelines. DESIGN: We retrospectively reviewed the initial five-year dermatology follow-up visit frequencies of melanoma patients and extracted basic demographic and clinical data from their medical records...
December 2017: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/29398454/melanoma-in-the-very-elderly-management-in-patients-85years-of-age-and-over
#9
Matthew J Rees, Henry Liao, John Spillane, David Speakman, Chris McCormack, Simon Donahoe, Miki Pohl, Angela Webb, David Gyorki, Michael A Henderson
OBJECTIVES: Melanoma treatment in the elderly can entail complex decision making. This study characterizes the presentation, management, and outcome of melanoma in the very elderly. METHOD: Retrospective review of all patients in their 85th year or older presenting to a tertiary referral cancer centre between 2000 and 2012 with American Joint Committee on Cancer stages 0-II cutaneous melanoma. RESULTS: 127 patients, 26 with in-situ disease and 101 with stages I-II disease, were included...
February 2, 2018: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29394463/primary-orbital-melanoma-treated-with-orbital-exenteration-and-postoperative-radiotherapy-a-case-report-and-review-of-the-literature
#10
Christopher P Haskins, Sommer Nurkic, Kristianna M Fredenburg, Peter T Dziegielewski, William M Mendenhall
BACKGROUND: We report on a patient with human immunodeficiency virus (HIV)-positive disease with a primary orbital melanoma treated with surgery and adjuvant radiation. METHODS: A 53-year-old woman with HIV-positive disease presented with left-sided progressive ipsilateral vision loss and proptosis. An MRI scan revealed a mass-enhancing lesion measuring 2.1 × 2.6 × 2.5 cm abutting the optic nerve. The patient underwent left orbital exenteration with temporalis flap reconstruction, pathology revealing malignant melanoma, stage T1N0M0...
February 2, 2018: Head & Neck
https://www.readbyqxmd.com/read/29393978/hu-antigen-r-hur-heterogeneous-expression-quantification-as-a-prognostic-marker-of-melanoma
#11
Nicolas Liaudet, Marylise Fernandez, Lionel Fontao, Gürkan Kaya, Rastine Merat
BACKGROUND: Prognostic markers for melanoma, particularly for stage II disease, are needed for the risk benefit evaluation of future adjuvant therapies. The mainly nuclear RNA-binding protein HuR regulates the protein expression of thousands of mRNAs, its own heterogeneous expression could therefore reflect tumor heterogeneity and plasticity. Here, we evaluate its quantification in primary melanoma as a marker of metastatic outcome. METHODS: We conducted an immunohistochemistry-based automated quantification of HuR nuclear expression heterogeneity in primary melanomas most with Breslow thickness ≥ 1 mm and calculated the dimensionless fourth moment, i...
February 2, 2018: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/29389234/duration-of-anti-programmed-death-1-therapy-in-advanced-melanoma-how-much-of-a-good-thing-is-enough
#12
Nikhil I Khushalani
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
February 1, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29384960/dabrafenib-plus-trametinib-for-compassionate-use-in-metastatic-melanoma-a-strobe-compliant-retrospective-observational-postauthorization-study
#13
Salvador Martín Algarra, Virtudes Soriano, Luis Fernández-Morales, Miguel-Ángel Berciano-Guerrero, Karmele Mujika, José Luis Manzano, Teresa Puértolas Hernández, Ainara Soria, Delvys Rodríguez-Abreu, Enrique Espinosa Arranz, Javier Medina Martínez, Ivan Márquez-Rodas, Jordi Rubió-Casadevall, María Eugenia Ortega, José Miguel Jurado García, María José Lecumberri Biurrun, Isabel Palacio, María Rodríguez de la Borbolla Artacho, Javier Pérez Altozano, Victoria Eugenia Castellón Rubio, Almudena García, Pablo Luna, Anabel Ballesteros, Ovidio Fernández, Jose Antonio López Martín, Alfonso Berrocal, Ana Arance
The main objective of the study was to evaluate the efficacy and safety of dabrafenib alone or combined with trametinib for compassionate use in patients with metastatic melanoma.This retrospective, observational study involved 135 patients with unresectable stage IIIC or stage IV melanoma from an expanded-access program at 30 Spanish centers.Forty-eight patients received dabrafenib monotherapy and 87 received combination dabrafenib and trametinib; 4.4% and 95.6% of the patients had stage IIIC and IV melanoma, respectively...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29361468/neoadjuvant-plus-adjuvant-dabrafenib-and-trametinib-versus-standard-of-care-in-patients-with-high-risk-surgically-resectable-melanoma-a-single-centre-open-label-randomised-phase-2-trial
#14
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, Alexandre Reuben, Miles C Andrews, Merrick I Ross, Isabella C Glitza, Janice Cormier, Wen-Jen Hwu, Hussein A Tawbi, Sapna P Patel, Jeffrey E Lee, Jeffrey E Gershenwald, Christine N Spencer, Vancheswaran Gopalakrishnan, Roland Bassett, Lauren Simpson, Rosalind Mouton, Courtney W Hudgens, Li Zhao, Haifeng Zhu, Zachary A Cooper, Khalida Wani, Alexander Lazar, Patrick Hwu, Adi Diab, Michael K Wong, Jennifer L McQuade, Richard Royal, Anthony Lucci, Elizabeth M Burton, Sangeetha Reddy, Padmanee Sharma, James Allison, Phillip A Futreal, Scott E Woodman, Michael A Davies, Jennifer A Wargo
BACKGROUND: Dual BRAF and MEK inhibition produces a response in a large number of patients with stage IV BRAF-mutant melanoma. The existing standard of care for patients with clinical stage III melanoma is upfront surgery and consideration for adjuvant therapy, which is insufficient to cure most patients. Neoadjuvant targeted therapy with BRAF and MEK inhibitors (such as dabrafenib and trametinib) might provide clinical benefit in this high-risk p opulation. METHODS: We undertook this single-centre, open-label, randomised phase 2 trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA)...
January 17, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29356588/experiences-of-care-of-adolescents-and-young-adults-with-cancer-in-australia
#15
Victoria White, Gemma Skaczkowski, Kate Thompson, Helen Bibby, Michael Coory, Ross Pinkerton, Wayne Nicholls, Lisa M Orme, Rachel Conyers, Marianne B Phillips, Michael Osborn, Rosemary Harrup, Antoinette Anazodo
PURPOSE: To examine the care experiences of Australian Adolescents and Young Adults (AYAs) with cancer during a period when youth cancer services (YCS) were developing across the country. METHODS: A cross-sectional, self-report survey completed by 207 recently diagnosed AYAs with cancer, recruited from the population-based cancer registries of Australia's two most populous states. AYAs were 15 to 24 years old when diagnosed with any form of cancer (except melanoma <3 mm or stage I/II)...
January 22, 2018: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/29350487/pediatric-patients-with-cutaneous-melanoma-a-european-study
#16
Ines B Brecht, Angela De Paoli, Gianni Bisogno, Daniel Orbach, Dominik T Schneider, Ulrike Leiter, Sonja Offenmueller, Giovanni Cecchetto, Jan Godzinski, Ewa Bien, Teresa Stachowicz-Stencel, Tal Ben-Ami, Stefano Chiaravalli, Andrea Maurichi, Gian Luca De Salvo, Silvia Sorbara, Christine Bodemer, Claus Garbe, Yves Reguerre, Andrea Ferrari
INTRODUCTION: Cutaneous melanoma is rare in childhood and published studies have mainly been retrospective single-institution series or small case series. Given the absence of clinical protocols dedicated to pediatric melanoma, the treatment approach is generally extrapolated from the ones applied to adults. METHODS: Coordinated by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT), this study collected patients prospectively registered between 2002 and 2012 under national cooperative projects dedicated to rare pediatric tumors in Italy, Poland, Germany, and France...
January 19, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29350463/brim-p-a-phase-i-open-label-multicenter-dose-escalation-study-of-vemurafenib-in-pediatric-patients-with-surgically-incurable-braf-mutation-positive-melanoma
#17
Julia C Chisholm, Jozef Suvada, Ira J Dunkel, Michela Casanova, Weijiang Zhang, Natasha Ritchie, YounJeong Choi, Jane Park, Meghna Das Thakur, Stephen Simko, Nga Wan Rachel Tam, Andrea Ferrari
BACKGROUND: Vemurafenib, a selective inhibitor of BRAF kinase, is approved for the treatment of adult stage IIIc/IV BRAF V600 mutation-positive melanoma. We conducted a phase I, open-label, dose-escalation study in pediatric patients aged 12-17 years with this tumor type (NCT01519323). PROCEDURE: Patients received vemurafenib orally until disease progression. Dose escalation was conducted using a 3 + 3 design. Patients were monitored for dose-limiting toxicities (DLTs) during the first 28 days of treatment to determine the maximum tolerated dose (MTD)...
January 19, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29344558/therapeutic-potential-of-bleomycin-plus-suicide-or-interferon-%C3%AE-gene-transfer-combination-for-spontaneous-feline-and-canine-melanoma
#18
Lucrecia Agnetti, Chiara Fondello, Marcela S Villaverde, Gerardo C Glikin, Liliana M E Finocchiaro
We originated and characterized melanoma cell lines derived from tumors of two feline and two canine veterinary patients. These lines reestablished the morphology, physiology and cell heterogeneity of their respective parental tumors. We evaluated the cytotoxicity of bleomycin (BLM) alone, or combined with interferon-β (IFN-β) or HSVtk/GCV suicide gene (SG) lipofection on these cells. Although the four animals presented stage III disease (WHO system), SG treated feline tumors displayed stable disease in vivo, while the canine ones exhibited partial response...
November 2017: Oncoscience
https://www.readbyqxmd.com/read/29342436/iris-melanoma-outcomes-based-on-the-american-joint-committee-on-cancer-classification-eighth-edition-in-432-patients
#19
Carol L Shields, Maura Di Nicola, Vladislav P Bekerman, Swathi Kaliki, Carolina Alarcon, Enzo Fulco, Jerry A Shields
PURPOSE: The American Joint Committee on Cancer (AJCC) classification was updated to the eighth edition in January 2017, providing staging for iris melanoma. This study evaluated outcomes of iris melanoma per the AJCC classification, eighth edition. DESIGN: Retrospective case series. PARTICIPANTS: Four hundred thirty-two patients with iris melanoma. METHODS: Management including tumor resection, plaque radiotherapy, or enucleation...
January 13, 2018: Ophthalmology
https://www.readbyqxmd.com/read/29327065/blood-predictive-biomarkers-for-nivolumab-in-advanced-melanoma
#20
Edouard Chasseuil, Mélanie Saint-Jean, Hannah Chasseuil, Lucie Peuvrel, Gaëlle Quéreux, Jean-Michel Nguyen, Aurélie Gaultier, Emilie Varey, Amir Khammari, Brigitte Dréno
Nivolumab response rate is 40% in metastatic melanoma. Few studies have evaluated pre-treatment biomarkers predictive of response. The aim of this study was to identify potential peripheral blood biomarkers associated with survival in patients with advanced melanoma treated with nivolumab. All advanced melanoma cases treated with anti-programmed cell death protein 1 (anti-PD1) over a 3-year period in the Dermato-Oncology Department, Nantes, France were identified. For each case, 9 potential blood biomarkers were identified...
December 20, 2017: Acta Dermato-venereologica
keyword
keyword
62301
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"